Sanara MedTech (NASDAQ:SMTI) Issues Earnings Results

Sanara MedTech (NASDAQ:SMTI) posted its quarterly earnings results on Tuesday. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07), Zacks reports. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. The company had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million.

Here are the key takeaways from Sanara MedTech’s conference call:

• Revenue milestone: Sanara exceeded $100 million of net revenue in 2025 ($103.1M, +19% YoY) while maintaining a roughly 40-person field sales force, highlighting scalability of its hybrid commercial model.
• Profitability and cash generation improved: Full-year gross margin expanded to ~93% (~200 bps improvement), adjusted EBITDA rose to $17M (+86% YoY), and cash from operations was $6.8M versus $24K used in 2024.
• Distribution catalyst — BIASURGE won Vizient’s Innovative Technology contract effective Jan 1, 2026, providing access to ~1,800 facilities and a meaningful commercial runway for adoption.
• Forward visibility — management introduced and reaffirmed 2026 net revenue guidance of $116M–$121M (13%–17% growth) and Q1 revenue guidance of ~$26.7M–$27.2M, signaling confidence in near-term execution.
• Balance sheet and expense risks — cash was $16.6M while long-term debt increased to $46M, Q4 continuing-operations net loss was $1.1M, and operating expenses rose partly due to a $1.8M non-cash IP impairment, indicating leverage and near-term cost headwinds.

Sanara MedTech Stock Down 8.3%

Sanara MedTech stock traded down $1.51 during trading on Wednesday, reaching $16.57. 175,803 shares of the company’s stock were exchanged, compared to its average volume of 63,550. The company’s 50-day moving average is $20.36 and its two-hundred day moving average is $24.67. The company has a debt-to-equity ratio of 7.34, a quick ratio of 1.60 and a current ratio of 1.80. Sanara MedTech has a 52-week low of $16.16 and a 52-week high of $35.95. The firm has a market cap of $147.48 million, a price-to-earnings ratio of -3.89 and a beta of 1.04.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Stonebridge Wealth Management LLC bought a new stake in Sanara MedTech in the 2nd quarter valued at about $3,397,000. Royal Bank of Canada grew its position in Sanara MedTech by 127.3% in the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after purchasing an additional 65,887 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after purchasing an additional 42,237 shares during the period. Squarepoint Ops LLC increased its stake in shares of Sanara MedTech by 343.4% in the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after purchasing an additional 24,305 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Sanara MedTech during the fourth quarter valued at approximately $355,000. Institutional investors and hedge funds own 8.10% of the company’s stock.

Key Sanara MedTech News

Here are the key news stories impacting Sanara MedTech this week:

• Positive Sentiment: Revenue and guidance: Net revenue rose ~5% year‑over‑year to $27.5M for Q4, and management reaffirmed full‑year 2026 financial guidance — a stabilizing signal for future growth. GlobeNewswire Release
• Neutral Sentiment: Market reaction intraday was mixed — some headlines noted a >3% intraday rise despite the earnings miss, indicating short‑term buyers stepped in after results. MSN Investing.com
• Neutral Sentiment: Transcript available: The Q4 2025 earnings call transcript is published for investors who want management color on results and 2026 outlook. Seeking Alpha Transcript
• Negative Sentiment: Earnings miss and weak profitability: Reported EPS missed consensus (company reported a loss per MarketBeat/press materials vs. analyst estimates), with a negative net margin (~‑36.8%) and negative ROE — profitability metrics that typically pressure small‑cap medical device stocks. Zacks Company Press Release
• Negative Sentiment: Short‑interest reporting confusion: Multiple short‑interest notices claim a “large increase” but list zero shares/NaN values — a data anomaly that creates uncertainty and can amplify volatility if market participants interpret it as rising short activity (impact unclear). (Data sources published on March 24.)
• Negative Sentiment: Technical and balance sheet concerns: The stock trades below its 50‑ and 200‑day moving averages and near its 52‑week low; the company also shows a high reported debt‑to‑equity ratio — factors that can pressure sentiment for a small‑cap healthcare name.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of Sanara MedTech in a research note on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $41.00.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.